Literature DB >> 165492

Cyclic AMP and immune responses: changes in the splenic level of cyclic AMP during the response of mice to antigen.

O J Plescia, I Yamamoto, T Shimamura.   

Abstract

Intravenous injection of sheep erythrocytes into normal immunologically competent C57BL/6J mice results in significant and characteristic changes in the splenic level of 3':5'-cAMP with initiation of the immune response and proliferation of antibody-forming cells. The level increases 2- to 3-fold initially, peaks at 2 min, and returns to base level in an hour. Between 2 and 5 days there is a decrease, followed by a peak when the rate of proliferation of antibody-forming cells is maximal. Changes in splenic level of cAMP are thus transitory and biphasic, and they occur only in response to foreign substances that are immunogenic, such as heterologous erythrocytes, and not to antigenically inert carbon particles. They are also dependent upon the dose of immunogen. Moreover, the double-stranded hybrid of polyadenylate and polyuridylate, which acts synergistically with antigen in stimulating endogenous cAMP, is immuno-enhancing if given with sheep erythrocytes when the cAMP level is increasing, and immunosuppresive if given when cAMP is decreasing. These data provide direct evidence for a role of cAMP as a mediator in the activation and proliferation of immunocytes stimulated by antigen. With knowledge of the transitory and biphasic nature of the cAMP response induced by antigen, one can avoid indiscriminate use of drugs that modify the level of endogenous cAMP and instead employ them rationally in controlling the immune response, enhancing or suppressing it as desired.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 165492      PMCID: PMC432426          DOI: 10.1073/pnas.72.3.888

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  7 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Evidence that cyclic AMP is not the chemical mediator of the metabolic changes accompanying phagocytosis.

Authors:  E Schell-Frederick; J Van Sande
Journal:  J Reticuloendothel Soc       Date:  1974-02

3.  An improved protein binding assay for cyclic AMP.

Authors:  C O Brostrom; C Kon
Journal:  Anal Biochem       Date:  1974-04       Impact factor: 3.365

4.  Biphasic effect of cyclic AMP on an immune response.

Authors:  H S Teh; V Paetkau
Journal:  Nature       Date:  1974-08-09       Impact factor: 49.962

Review 5.  Modulation of inflammation and immunity by cyclic AMP.

Authors:  H R Bourne; L M Lichtenstein; K L Melmon; C S Henney; Y Weinstein; G M Shearer
Journal:  Science       Date:  1974-04-05       Impact factor: 47.728

6.  Discussion paper: isolation and characterization of functional antigen-carrying T cells.

Authors:  O J Plescia; J S Hursch
Journal:  Ann N Y Acad Sci       Date:  1973-05-31       Impact factor: 5.691

7.  A protein binding assay for adenosine 3':5'-cyclic monophosphate.

Authors:  A G Gilman
Journal:  Proc Natl Acad Sci U S A       Date:  1970-09       Impact factor: 11.205

  7 in total
  3 in total

1.  Pharmacological control of the hormonally modulated immune response. II. Blockade of antibody production by a combination of drugs acting on neuroendocrine functions. Its prevention by gonadotropins and corticotrophin.

Authors:  W Pierpaoli; G J Maestroni
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

2.  Pharmacologic effects of autacoids on subsets of T cells. Regulation of expression/function of histamine-2 receptors by a subset of suppressor cells.

Authors:  M M Khan; P Sansoni; E G Engleman; K L Melmon
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

3.  Conformational basis for the activation of adenylate cyclase by adenosine.

Authors:  D L Miles; D W Miles; H Eyring
Journal:  Proc Natl Acad Sci U S A       Date:  1977-06       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.